Key result
Annual CV screening and risk optimization are recommended to mitigate therapy-related cardiotoxicity in cancer survivors.
Why the study?
Cancer survivors face an elevated risk of cardiovascular toxicity impacting health and life expectancy, prompting a summary of evidence, practical recommendations, and literature gaps regarding post-cancer cardiovascular care.
This document summarizes evidence and provides practical recommendations for cardiovascular surveillance and risk factor optimization in cancer survivors to mitigate cancer therapy-related cardiovascular toxicity.
Supports CV surveillance in cancer survivors; leaves open need for prospective trials to validate recommendations.
Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy-related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy-related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.
No takes yet. Share an insight, caveat, or question.
Blaes et al. (2025) conducted a review in Cancer therapy-related cardiovascular toxicity. Cardiovascular surveillance was evaluated. Annual clinical screenings and optimization of cardiovascular risk factors are recommended for all cancer survivors to mitigate the elevated risk of cancer therapy-related cardiovascular toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: